Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

UBS upgraded ResMed (RMD) to Buy from Neutral with a price target of $290, up from $255. The firm thinks consensus is too cautious in the ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $162.95, a high estimate of ...

Blue Square Asset Management LLC lifted its position in shares of JPMorgan Chase & Co. (NYSE:JPM – Free Report) by 2.5% in ...

Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades.

Algert Global LLC acquired a new stake in shares of Microsoft Co. (NASDAQ:MSFT – Free Report) in the third quarter, according ...

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Resmed (RMD – Research Report) on January 29 and set a price target of $238.00.

Triton International Limited (the "Company" or "Triton") today announced the pricing of an underwritten offering of 6,000,000 ...

Imposing higher capital requirements on UBS as a systemically relevant bank will usher in higher costs for companies and ...

Britain’s biggest supermarket chain used data to gain an edge, but as rivals start to catch up, Michael Fahy looks at whether its growth prospects are worth buying into ...